To fund clinical trials and advanced medical technologies that seek to find a cure and offer improved treatment opportunities and early detection for neurodegenerative diseases and pancreatic cancer.
There are nearly 5.7 million people living with Alzheimer’s disease and with the growing aging population and the increased prevalence of AD, that number is predicted to skyrocket. To date, there is no cure for Alzheimer’s disease. While there have been a handful of FDA-approved drugs for the treatment of Alzheimer’s, these drugs, at best, marginally slow down the progression of the disease and come with a host of intense side effects. Diagnosing this disease has also presented a major challenge to the scientific community as brain imaging showing the hallmark AD plaques is not only expensive, it is only conclusive once the disease has fully taken hold.
Over the past few decades, our understanding of the inner-workings of this disease has grown immensely and great progress has been made in mapping its course. Our growing knowledge of the human genome and advances in gene therapy are very exciting fields in the fight against Alzheimer’s. There is also great momentum in the development of better and cheaper biomarkers to aid in the early diagnosis of this disease. Though it is hard to be optimistic about a disease that has evaded treatment for so long, there are new discoveries and improved technologies being developed daily as the search for a cure continues.
Our goal at the FFABW is to fund clinical trials and advanced medical technologies that seek to find a cure and offer improved treatment opportunities and early detection for the millions of people suffering from Alzheimer’s disease. We have partnered with the Alzheimer’s Drug Discovery Foundation to achieve this goal. They are laser-focused on finding new and better drugs for Alzheimer’s and we remain hopeful that a cure will be found as we join them in this endeavor. To learn more about the ADDF, please visit the link above.
Formed in 1980, the Alzheimer’s Association is the leading voluntary health organization in Alzheimer’s care, support and research. Their mission is to eliminate Alzheimer’s disease through the advancement of research, to provide and enhance care and support for all affected and to reduce the risk of dementia through the promotion of brain health.
For over 100 years, Children’s Healthcare of Atlanta has been delivering state of the art children’s medical care. Whether treating a toddler during an emergency or helping a teen through chemotherapy treatments, they make it their mission to provide the best possible care and experience for every child. In 2019, they provided care for nearly 400,000 children, 60% of whom were on Medicaid or were entirely uninsured. Our work with Children’s Healthcare of Atlanta has centered on supporting their facilities and capabilities in treating children with neuromuscular conditions.
Multiple sclerosis (MS) is an unpredictable, degenerative, neurological disease that disrupts the flow of information within the brain and between the brain and body. It is the leading neurological cause of disability in young adults. Approximately 40% of people with MS have a progressive form of the disease, experiencing debilitating symptoms including fatigue, pain, cognitive challenges, difficulty walking and decreasing ability to work and function independently. People with progressive MS face uncertainty, losing ground each day which can cause a sense of helplessness.
While significant progress has been made in treating relapsing-remitting MS with 16 FDA approved disease-modifying treatments, there is only one approved treatment for a small sub-set of people living with primary progressive MS. This urgent, worldwide need for breakthrough treatments resulted in the formation of the International Progressive MS Alliance. The Alliance has brought together the global MS community including MS organizations, leading research institutions, the pharmaceutical industry and people affected by progressive MS to develop life-changing treatments.
For more information, please visit the MS Alliance’s website. www.progressivemsalliance.org
YouTube Video: Living with Progressive MS https://youtu.be/1BlufiE46Ps
One of our founder’s close family friends lives with MS and he has supported the National MS Society (USA) for over a decade. In 2018, the Foundation for a Better World made the largest single investment by a private foundation for Progressive MS research to fund a research and drug development program for the International Progressive MS Alliance. Dr. Gianvito Martino at the San Raffaele Hospital and Scientific Institute in Milan, Italy is leading a global collaborative project to identify molecules that may provide protection to nerve cells or promote repair resulting from damage caused by progressive MS.
Tom and Beatriz were recognized and inducted into the Circle of Distinction at the 2018 National MS Society Leadership Conference recognizing the profound impact the Foundation for a Better World has had in accelerating the work of the International Progressive MS Alliance and helping people dealing with this aggressive form of MS.
The National MS Society envisions are world free of MS and they are tackling the disease comprehensively. Through the acceleration and funding of advanced research, empowering those affected by MS, improving quality of life, and promoting advocacy to increase support for MS, the National MS Society is a leading platform in the quest to end MS.
Ohio State University’s Center for Electron Microscopy and Analysis is a leading, innovative world-class facility and program for analytical electron microscopy. With one of the largest concentrations of electron and ion beam analytical microscopy instruments in any North American institution, CEMAS brings together multidisciplinary expertise to drive synergy, amplify characterization capabilities and challenge what is possible in analytical electron microscopy. Through these advanced material characterization techniques, CEMAS hopes to deliver solutions for medicine, advanced manufacturing, environmental science, energy harvesting and storage, and healthcare.
The Pancreatic Cancer Action Network is dedicated to fighting the world’s toughest cancer on all fronts: research, clinical initiatives, patient services and advocacy. Their newly launched Precision Promise program is an innovative adaptive clinical trial platform designed to serve as a catalyst to accelerate pancreatic cancer drug development, de-risk industry participation, increase clinical trial enrollment and transform the way clinical research is done for pancreatic cancer patients.
Directly Funded Projects
- Dr. Katerina Akassoglou
- Gladstone Institutes
- Developing cell immunotherapies for neurodegenerative diseases
- Initiated: 2021
- Duration: 18 months
- Dr. Tatiana Hurtado de Mendoza
- Targeting neoantigens to pancreatic tumors to enable immunotherapy
- Initiated: 2021
- Duration: 3 years
- Dr. Gianvito Martino
- San Raffaele Hospital & The International Progressive MS Alliance
- Bioinformatics and cell reprogramming to develop an in vitro platform to discover new drugs for progressive multiple sclerosis.
- Initiated: 2018
- Duration: 4 years